RankAlpha logo
Back to Rankings

XGN

ExagenD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
The bullish read is that Exagen is showing a real commercial-improvement pattern: Q1 2026 delivered record revenue, 12% year-over-year growth, 10% AVISE CTD volume growth, higher ASP, and better adjusted EBITDA, while full-year guidance was maintained. That combination supports a cautious rerating case if Q2 confirms the gains are repeatable.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +1.8.
What can break
Failure to sustain AVISE CTD volume and ASP gains could quickly pressure the current improvement narrative.
Momentum
99
Value
41
Sentiment
32
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.75 · Bull $7.50 · Bear $3.20Analysis 2026-06-25; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-25 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-09-09

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions

Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $9.86
Why
Momentum99 · Δ7d -0.3
Value41 · Δ7d 0.0
Sentiment32 · Δ7d +1.8
So what
Weak posture (Net Neutral). Prioritize risk control and patience.

Confirming evidence

  • • Sentiment remains the lead driver in the composite, 7D delta +1.8.

Contradictions & invalidation

  • • Failure to sustain AVISE CTD volume and ASP gains could quickly pressure the current improvement narrative.
  • • Low sell-side coverage and loose peer comparability reduce external validation and can increase volatility around each quarterly update.
  • • The bearish read is that Exagen still remains loss-making, liquidity is limited for a small-cap healthcare name, and the stock may need multiple more quarters of clean execution before investors fully trust the path to cash-flow positivity.

Catalyst clock

2026-06-30

Thin post-earnings revision support could help sentiment, but coverage is sparse

Lead driver: Sentiment · See AI snapshot
Momentum
99
9% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
+1.0
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
32
62% active weight
Current posture
7d trendImproving
Δ7d
+1.8
Δ21d
-8.1
Why this grade

Composite grade D. Momentum 99.1 / Value 41.2 / Sentiment 31.7

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-06-25. Scenario method

B+
Bull case
25%
Probability
Target price
$7.50
Analysis reference price unavailable
Analysis 2026-06-25 · RankAlpha Sentiment Codex
Most likely
B
Base case
45%
Probability
Target price
$5.75
Analysis reference price unavailable
Analysis 2026-06-25 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$3.20
Analysis reference price unavailable
Analysis 2026-06-25 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$162.31M
Beta
1.91
Shares Out
24.23M
P/E (TTM) · Derived
-7.2
P/S (TTM)
2.12
P/FCF (TTM) · Derived
-21.14
Rev YoY
+15.9%
EPS YoY
-37.1%
Gross Margin
+58.6%
Op Margin
-18.6%
Net Debt
-$4.55M
Current Ratio
3.18
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data